LOS ANGELES--(BUSINESS WIRE)--Cougar Biotechnology, Inc. (NASDAQ:CGRB) today announced that results from ongoing Phase I and Phase II clinical trials of Cougar’s investigational drug, CB7630 (abiraterone acetate), were presented at the ASCO Genitourinary Cancers Symposium that is currently taking place in San Francisco, California. The data was presented today in both an oral presentation and two poster presentations.
